Clinical Applications of DNA Methylation Markers: Promises and Pitfalls
Conference Recording Feb 01, 2014
About the Speaker Prof. dr. Manon van Engeland received her Master degree Biological Health Sciences in 1995 and her PhD in Molecular Cell Biology in 1999 at Maastricht University. After a postdoctoral fellowship at the Johns Hopkins University School of Medicine (2000-2001; Herman lab) she returned to Maastricht University and founded the ‘Cancer Pathology Laboratory’ of the dept. of Pathology. In 2003 she was appointed as assistant professor and in 2007 as associate professor. In March 2011, she was appointed as extraordinary professor ‘Pathobiology of cancer: specifically the role of epigenetics’ at Maastricht University. She is division leader Oncology at GROW-the School for Oncology and Developmental Biology since 2010. Her lab is focussing on the identification of early detection-, prognostic and predictive epigenetic markers for cancer and the functional validation of the tumor suppressor functions of the identified candidate markers. Abstract Colorectal cancer has predominantly been considered a genetic disease, characterized by sequential accumulation of genetic alterations. Growing evidence indicates that epigenetic alterations add an additional layer of complexity to the pathogenesis of colorectal cancer, and characterize a subgroup of colorectal cancers with a distinct etiology and prognosis. Here I discuss recent data on epigenetic regulation of gene expression in CRC and describe how the understanding of these processes will alter the management of colorectal cancer. I also discuss the challenges that we face in bringing epigenetic markers to the clinic.